Why A One-Source-One-Location Outsourcing Model Makes Sense

Like many biopharma companies, you’ve probably concluded that outsourcing some portion of your drug development and clinical and commercial manufacturing is the best strategy for maximizing your speed to market and balancing the challenges of a growing portfolio. You already know all of the benefits of outsourcing; you just need to choose the right partners — or partner.

However, with an increasing number of mergers and acquisitions, there is a capacity crunch when it comes to CDMOs. “During the last few years there has been a fair amount of mergers and acquisitions in the outsourcing space,” says Ryan Hawkins, Vice President and Chief Operating Officer at Cook Pharmica. “As a result, the availability of CDMOs has become a more critical consideration. Add to that the need to maintain high-quality standards regarding the development and manufacturing process, and sponsors have a complicated decision to make.”